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Introduction: Eosinophils have been long implicated in anti-parasite immunity and 36	
allergic diseases and, more recently, in  regulating adipose tissue homeostasis. The 37	
metabolic processes that govern eosinophils, particularly upon activation, are unknown.  38	
 39	
Methods: Peripheral blood eosinophils were isolated for analysis of metabolic 40	
processes using extracellular flux analysis and individual metabolites by stable isotope 41	
tracer analysis coupled to gas chromatography-mass spectrometry following treatment 42	
with IL-3, IL-5 or granulocyte-macrophage colony-stimulating factor (GM-CSF). 43	
Eosinophil metabolism was elucidated using pharmacological inhibitors.  44	
 45	
Results: Human eosinophils engage a largely glycolytic metabolism but also employ 46	
mitochondrial metabolism. Cytokine stimulation generates citric acid cycle (TCA) 47	
intermediates from both glucose and glutamine revealing this previously unknown role 48	
for mitochondria upon eosinophil activation. We further show that the metabolic 49	
program driven by IL-5 is dependent on the STAT5/PI3K/Akt signalling axis and that 50	
nicotinamide adenine dinucleotide phosphate oxidase (NOX)-dependent ROS 51	
production might be a driver of mitochondrial metabolism upon eosinophil activation.  52	
 53	
Conclusion: We demonstrate for the first time that eosinophils are capable of metabolic 54	
plasticity, evidenced by increased glucose-derived lactate production upon ROS 55	
inhibition. Collectively this study reveals a role for both glycolysis and mitochondrial 56	
metabolism in cytokine-stimulated eosinophils. Selective targeting of eosinophil 57	
metabolism may be of therapeutic benefit in eosinophil-mediated diseases and 58	
regulation of tissue homeostasis.  59	
 60	
 61	






Human eosinophils reside primarily in haematopoietic and mucosal tissues. Interest in 66	
eosinophil activity stems predominantly from their role in anti-parasite immunity and 67	
allergic disease1-5 but there is growing interest in their role in tissue homeostasis, 68	
especially adipose tissue6. Eosinophil-mediated effector function involves 69	
degranulation, the release of antimicrobial cytotoxic molecules, and the respiratory 70	
burst2 yet we know little about the immunometabolic processes that underpin these 71	
activities. Activation of other granulocyte populations such as neutrophils and mast 72	
cells enhances glycolysis to support biosynthetic intermediate production and rapid 73	
ATP generation7,8. Eosinophil metabolism is assumed to be largely homologous to that 74	
of neutrophils, where, despite the presence of mitochondria, energy production stems 75	
primarily from glycolysis5,9,10.  76	
 77	
Non-metabolic roles for mitochondria within eosinophils have been the focus of several 78	
investigations. Mitochondrial DNA can be released in a ‘catapult-like’ fashion from 79	
eosinophils and contributes to antibacterial defence, although this remains controversial 80	
and has yet to be confirmed11,12. Furthermore, the initiation of apoptosis has been 81	
reported as an alternative role to respiration for eosinophil mitochondria10. As 82	
eosinophils produce large amounts of nicotinamide adenine dinucleotide phosphate 83	
oxidase (NOX)2-dependent extracellular reactive oxygen species (ROS) upon 84	
activation13-15, it is commonly thought that oxygen consumption by eosinophils 85	
supports ROS production rather than oxidative phosphorylation (OXPHOS). Contrary 86	
to this, human eosinophils are sensitive to oligomycin (mitochondrial ATP synthase 87	
inhibitor), suggesting that in addition to glycolysis, mitochondria can indeed contribute, 88	
at least in part, to ATP production5. As such, the role of the mitochondria in eosinophils 89	
remains unclear and requires investigation.  90	
 91	
Glycolysis has been reported to be the main source of ATP in numerous cell types16-18. 92	
This is especially true for immune cells such as T cells and mast cells, which undergo 93	
a glycolytic switch upon activation to support rapid ATP production19,20. Little is 94	
known about the role of glycolysis in eosinophil-mediated immunity, but glycolysis-95	
derived ATP is essential for the removal of schistosomula by human eosinophils21 and 96	
cytokines such as IL-3, IL-5, granulocyte-macrophage colony-stimulating factor (GM-97	
CSF) and TNFα stimulate glucose uptake in these cells22. The anti-apoptotic cytokines 98	
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IL-3, IL-5, and GM-CSF, produced primarily by T cell subsets, fibroblasts, and 99	
epithelial cells, are critical for eosinophil activation and maturation2. Differential 100	
effects of IL-3, IL-5, and GM-CSF have been identified, with IL-3 generally being a 101	
weaker inducer of eosinophil activation than either IL-5 or GM-CSF; IL-3 induces less 102	
glucose uptake, superoxide production and eosinophil-derived neurotoxin (EDN) 103	
release than IL-5 or GM-CSF22,23. However, IL-3 can prolong ribosomal protein S6 104	
signalling compared to IL-5 and GM-CSF, producing augmented levels of semaphorin-105	
7A and heightened protein translation24. Despite these differences in responses of 106	
eosinophils to IL-3, IL-5, and GM-CSF, the impact of these cytokines on human 107	
eosinophil metabolic adaptation that underpins these different functional outcomes has 108	
not been studied.  109	
 110	
Here, for the first time, we demonstrate that human eosinophils are metabolically plastic 111	
cells, up-regulating both glycolytic and TCA cycle intermediates upon activation. We 112	
show that IL-3, IL-5 and GM-CSF all increase glycolysis and importantly, that upon 113	
activation by these cytokines, eosinophils increase glutaminolysis and subsequent TCA 114	
cycling. This is significant as these cells were previously thought to not engage their 115	
mitochondria for metabolic purposes. In contrast to earlier studies10, we report that the 116	
IL-5-induced metabolic switch initiates glycolysis and enhances mitochondrial 117	
respiration in a mechanism that is dependent on the STAT5/PI3K/Akt axis. Finally, the 118	
ability of esoinophils to compensate for inhibition of ROS production and the 119	
asscioated reduced levels of TCA cycle intermediates by increased aerobic glycolysis 120	














Materials and Methods 133	
Human eosinophil isolation 134	
Human peripheral blood was collected from both male (n = 9) and female donors (n = 135	
25) aged between 18-70 years into heparinised VacuettesTM (Greiner Bio-one, 136	
Frickenhausen, Germany). We recruited both atopic and non-atopic donors with 137	
eosinophils comprising between 1-8% of total circulating leukocytes. Specific donor 138	
demographics can be found in supplementary table 1. All samples were collected with 139	
informed written consent and ethical approval was obtained from Wales Research 140	
Ethics Committee 6 (13/WA/0190). Eosinophils were isolated by negative selection 141	
using immunomagnetic microbeads (autoMACS; Miltenyi Biotec, Cologne, Germany). 142	



























Eosinophils increase glycolysis in response to cytokines 168	
In human eosinophils, IL-3, IL-5, and GM-CSF are the predominant cytokines 169	
associated with their activation25. Therefore, the effect of IL-3, IL-5 and GM-CSF on 170	
eosinophil metabolism was investigated.  171	
 172	
First, we investigated the mode of glucose transport in eosinophils. Gene expression 173	
levels of the main glucose transporters (GLUT1-4; SLC2A1-4) were determined using 174	
qPCR. While there was donor variability, GLUT1 (SLC2A1) and GLUT3 (SLC2A3) 175	
were expressed by all donors (Figure 1A). GLUT4 (SLC2A4) expression was not 176	
detected, and only some donors expressed detectable GLUT2 (SLC2A2; 3/7) (Figure 177	
1A). Uptake of a fluorescent glucose analogue 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-178	
yl)amino)-2-deoxyglucose (2-NBDG) did not differ between unstimulated and 179	
cytokine-stimulated eosinophils (Figure 1B).  180	
 181	
To further investigate the induction of glycolysis upon activation in eosinophils, we 182	
performed extracellular flux analysis measuring the extracellular acidification rate 183	
(ECAR) upon treatment with IL-3, IL-5, or GM-CSF. Eosinophils were starved of 184	
glucose, treated with cytokine followed by the reintroduction of glucose, then addition 185	
of the ATP synthase inhibitor oligomycin, with a final addition of 2-deoxy-D-glucose 186	
(2-DG) to arrest glycolysis over the timeline shown in Figure 1C. Here we discovered 187	
that after a period of glucose starvation, IL-5 or GM-CSF treatment increased ECAR 188	
significantly in comparison to either the control or IL-3-treated cells (Figure 1C-D). As 189	
there are multiple sources of acidification that may contribute to ECAR in eosinophils26-190	
28, we performed stable isotope tracer analysis (SITA) to determine the fate of glucose-191	
derived carbon atoms upon eosinophil activation. Eosinophils were activated with IL-192	
3, IL-5 or GM-CSF in the presence of 13C6-glucose for 4 h. If eosinophil metabolism is 193	
largely homologous to that of neutrophils29, i.e. glycolytic, then it would be expected 194	
that the majority of labelled carbon would be present as the m+3 mass isotopologue of 195	
lactate produced from the m+3 mass isotopologue of pyruvate (Figure 1E). These data 196	
demonstrate that IL-3, IL-5, or GM-CSF treatment promotes the incorporation of 13C 197	
atoms into pyruvate (Figure 1F-G) and lactate (Figure 1H-I). We also observed 13C 198	
labelled extracellular lactate within the supernatant (Figure 1J), excess production of 199	
lactate upon activation was also confirmed by a standard lactate assay (Figure 1K). 200	
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Collectively the data demonstrate that eosinophils treated with IL-3, IL-5 or GM-CSF 201	
switch to a glycolytic metabolism.  202	
 203	
Cytokine-stimulated eosinophils consume oxygen for ROS production 204	
It has been reported that eosinophils do not require their mitochondria for ATP 205	
production via OXPHOS10,30. However, mitochondria are diverse organelles with 206	
multiple metabolic roles. We confirmed the presence of mitochondria using 207	
transmission electron microscopy (Figure 2A). Mitochondrial function was assessed by 208	
measuring oxygen consumption rate (OCR) in the presence of IL-3, IL-5 or GM-CSF 209	
(Figure 2B). Baseline OCR was increased in IL-5 and GM-CSF treated cells post-210	
glucose starvation compared to the control and IL-3-treated cells (Figure 2C). We noted 211	
a decrease in OCR upon oligomycin treatment under all conditions, this is indicative of 212	
oxygen consumption for ATP generation, which is in agreement with a previous study5. 213	
Increasing the concentration of IL-3 delivered to the cells caused an increase in both 214	
ECAR and OCR (50 and 100 ng/mL; Figure 2D-E) suggestive of a differential kinetic 215	
response of eosinophils to IL-3 versus IL-5/GM-CSF. 216	
 217	
In our experiments, eosinophils clearly consume oxygen, especially in response to 218	
treatment with IL-5 or GM-CSF. However, oxygen consumption can occur 219	
independently of OXPHOS for processes such as respiratory burst, involving the 220	
generation of ROS and subsequently hydrogen peroxide via NOX enzymes13,14. To 221	
determine whether any of the cytokine-induced oxygen consumption was due to 222	
mitochondrial ROS production, we utilised the mitochondrial superoxide indicator 223	
MitoSOX and selected a time point to coincide with the extracellular flux assay (15 224	
minutes). Regardless of the cytokine used for stimulation, mitochondria did not 225	
contribute to oxygen consumption via ROS production at the time point measured; 226	
rotenone was used as a positive control (Figure 2F-G).  227	
 228	
To further investigate increased oxygen consumption upon stimulation we investigated 229	
whether IL-3, IL-5 and GM-CSF induce total ROS production. We determined total 230	
oxidative stress levels using the fluorescent probe CellROX and flow cytometry, 231	
phorbol 12-myristate 13-acetate (PMA) was used as a positive control. All three 232	
cytokines induced ROS production in comparison to the CellROX control with GM-233	
CSF being the most potent (Figure 2H-I). Using the inhibitor diphenyleneiodonium 234	
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(DPI), these responses were shown to be NOX-dependent, although this was only 235	
significant for GM-CSF and PMA-induced ROS production. These data raise the 236	
question of what happens to OCR when ROS production is inhibited, and we have 237	
addressed this in relation to IL-5 later in the manuscript, see Figure 5. 238	
 239	
Cytokine-stimulated eosinophils synthesise TCA cycle intermediates 240	
In addition to the generation of ATP and ROS, mitochondria can act as a biosynthetic 241	
hubs, synthesising TCA cycle intermediates and non-essential amino acids, however 242	
this has not been previously demonstrated in eosinophils. To test this, eosinophils were 243	
activated with IL-3, IL-5, or GM-CSF in the presence of 13C6-glucose for 4 h. Upon 244	
activation, eosinophils incorperated 13C-glucose into TCA cycle intermediates, such as 245	
citrate, succinate, malate and fumarate (Figure 3A-E). The metabolite pools analysed 246	
were mostly composed of  the unlabelled (m+0) or m+2 mass isotopologue (Figure 3F; 247	
Supplementary Figure 1A-C) indicating lack of sustained TCA cycling.  248	
 249	
Next, we determined whether TCA cycle intermediates are used as precursors for the 250	
synthesis of non-essential amino acids. Glutamate abundance was increased upon 251	
eosinophil stimulation with IL-3, IL-5 or GM-CSF (Figure 3G) and was largely present 252	
as the m+2 mass isotopologue (Figure 3H). While the eosinophils demonstrated 253	
production of glutamine and aspartate at baseline, cytokine stimulation had no further 254	
effect on the production of these. However, in comparison to the untreated control, 255	
cytokine-stimulated eosinophils had a reduced pool of 12C unlabelled amino acids, 256	
indicating consumption of these amino acids (Supplementary Figure 2A-D).  257	
 258	
Fully functional canonical TCA cycling requires two metabolite inputs: acetyl-CoA 259	
derived primarily from glucose and α-ketoglutarate derived from glutamine 260	
(Supplementary Figure 3A). Having established that eosinophils incorporate 13C-261	
glucose into TCA cycle intermediates, we next wanted to determine whether cytokine-262	
activated eosinophils engage glutaminolysis. To address this, eosinophils were 263	
activated with IL-3, IL-5 or GM-CSF in the presence of 13C-glutamine for 4 h. 264	
Incorporation of 13C into TCA intermediates was increased in IL-3, IL-5 or GM-CSF 265	
treated eosinophils compared to the untreated controls (Supplementary Figure 3B).  266	
 267	
The STAT5/PI3K/Akt axis governs the immediate metabolic response to IL-5  268	
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The development and clinical implementation of IL-5 targeting therapies in the 269	
treatment of asthma31 prompted us to consider the early signalling mechanisms that 270	
govern increased ECAR and OCR in response to IL-5 treatment. STAT5 is activated 271	
upon IL-3, IL-5 or GM-CSF ligation32,33, and in certain circumstances can be activated 272	
by ROS production via the common β chain34. We initially confirmed STAT5 273	
phosphorylation in eosinophils treated with IL-3, IL-5 and GM-CSF. All cytokines 274	
induced STAT5 phosphorylation, but this only reached significance above baseline for 275	
IL-5 and GM-CSF (Figure 4A). Next, we wanted to determine whether inhibition of 276	
STAT5 affected the immediate ECAR and OCR responses of eosinophils treated with 277	
IL-5. Pre-treatment with the STAT5 inhibitor Nʹ-((4-oxo-4H-chromen-3-278	
yl)methylene)nicotinohydrazide (STAT5i) completely abrogated the ECAR and OCR 279	
response in IL-5-stimulated eosinophils (Figure 4B-C). Calculations of ‘pre-cytokine’ 280	
and ‘post-cytokine’ data can be found at Supplementary Figure 4. 281	
 282	
In addition to cytokine-mediated STAT5 activation, both IL-5 and ROS can activate 283	
the PI3K/Akt axis34, therefore we next investigated the role of PI3K/Akt in human 284	
eosinophil metabolism. Treatment with either the PI3K inhibitor LY294002 or the 285	
Akt1/2 inhibitor, abrogated IL-5 stimulated induction of ECAR (Figure 4D). The same 286	
trend was observed for OCR whereby the PI3K inhibitor reduced the immediate 287	
induction of OCR in eosinophils treated with IL-5 (Figure 4E). However, treatment 288	
with the Akt1/2 inhibitor did not reduce IL-5 induced OCR (Figure 4E), suggesting 289	
other downstream PI3K pathways may be involved. These data show that one of the 290	
key immediate effects of IL-5 on eosinophils is up-regulation of glycolysis and this is 291	
dependent on the STAT5/PI3K/Akt axis. 292	
 293	
ROS inhibition reduces TCA cycling of IL-5 stimulated eosinophils 294	
To determine if the observed cytokine-stimulated metabolic changes in eosinophils 295	
were promoted by ROS production we next determined whether NOX had a role in 296	
increased ECAR and OCR with a focus on IL-5 as before. Bioenergetic analyses were 297	
used to show that DPI had no effect on IL-5-stimulated glycolysis (Figure 5A) but 298	
significantly reduced peak OCR (Figure 5B). SITA using 13C-glucose showed 299	
increased incorporation of 13C into pyruvate and lactate (indicated as an increased m+3 300	
mass isotopologue) in the presence of DPI (Figure 5C-D). This was accompanied by a 301	
reduction in the relative abundance of all TCA cycle intermediates (Figure 5E), 302	
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represented by a decreased abundance of the m+2 mass isotopologue (Figure 5F). DPI 303	
treatment negatively impacted on the synthesis of amino acids glutamate and aspartate, 304	
from 13C-glucose, by reducing 13C incorporation and the m+2 mass isotopologue 305	
(Figure 5G-H). Collectively these data demonstrate that NOX-mediated ROS may have 306	

































The study of eosinophil metabolism has been challenging, but recent years have seen 338	
the introduction of novel, refined technologies that allow metabolic analyses on low 339	
cell numbers with more sensitive readouts. This has been driven by the burgeoning field 340	
of immunometabolism and the increasingly recognised role of cellular metabolism in 341	
immune cell fate and function. Cellular metabolism through energy production (ATP) 342	
and biosynthetic intermediate generation orchestrates numerous effector roles such as 343	
cytokine production, migration and proliferation and can have a profound impact on 344	
various human pathologies35. Aside from their well-recognised energetic and 345	
biosynthetic roles, individual metabolites can have alternative roles. For example, TCA 346	
cycle metabolites, succinate and fumarate act as inflammatory signalling molecules. In 347	
LPS-stimulated macrophages, succinate stabilizes hypoxia-inducible factor-1α to 348	
promote increased glycolysis and IL-1β production9,36,37. Therefore, elucidating the 349	
cellular metabolic response of eosinophils not only improves our basic understanding 350	
of eosinophil function, especially how it might apply to tissue homeostasis, but has 351	
implications for revealing immunopathogenic and therapeutic strategies in eosinophilic 352	
disorders.  353	
 354	
The rapid engagement of aerobic glycolysis by eosinophils in response to cytokines 355	
demonstrated here was accompanied by accumulation of both intra- and extracellular 356	
lactate. Lactate creates an acidic environment in which eosinophils are known to thrive, 357	
such as in the lung38. Furthermore, excess lactate retains T cells in pro-inflammatory 358	
environments, curtailing their migration39. If the same occurred for eosinophils this 359	
would provide a mechanism to retain viable eosinophils in an acidic inflammatory 360	
tissue environment. This increased glycolytic rate that supports the accumulation of 361	
lactate is presumably due to either GLUT1 or GLUT3 mediated glucose uptake as these 362	
transporters were expressed by all donors, or through kinetic effects on the direct 363	
phosphorylation of glycolytic enzymes22. 364	
 365	
A key feature of the work presented here is clarity surrounding the role of mitochondria 366	
in eosinophil metabolism. It is well established that eosinophils utilise their 367	
mitochondria for apoptotic purposes10,30, however definitive metabolic contributions 368	
have remained elusive. Here, we confirmed that cytokine-stimulated eosinophils were 369	
sensitive to oligomycin treatment through a decrease in OCR. This indicates that 370	
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mitochondria in eosinophils have an important role in mediating metabolic responses 371	
to cytokines which is in agreement with a previous study5.  372	
 373	
Whilst the conversion of glucose to lactate seems to be the predominant metabolic 374	
pathway in response to cytokine stimulation, we used stable isotope tracing to show 375	
that eosinophils use both glucose and glutamine to generate TCA cycle intermediates 376	
and support OXPHOS upon activation. To our knowledge we are the first to provide 377	
evidence that carbons from glucose and glutamine are incorporated into TCA 378	
metabolites upon cytokine stimulation in eosinophils. Collectively, we reveal a novel 379	
role for human eosinophil mitochondria that extends beyond apoptosis and antibacterial 380	
defence. We demonstrate that eosinophils can utilise their mitochondria for TCA 381	
cycling contributions to OXPHOS and biosynthesis of amino acids. In support of a role 382	
for mitochondrial metabolism in eosinophils as we described here, a recent study 383	
indicated that peripheral blood eosinophils have increased oxidative parameters in 384	
comparison to neutrophils5. However, this interpretation was based solely on decreased 385	
oxygen consumption upon exposure to oligomycin and did not definitively characterise 386	
the metabolic fuels consumed by eosinophils.  387	
 388	
The effects of IL-3, IL-5 and GM-CSF on eosinophil metabolism were broadly similar. 389	
To better understand the signalling processes that govern cytokine-mediated changes 390	
to eosinophil cellular metabolism we chose to focus on a single cytokine. IL-5 was 391	
chosen as it is a therapeutic target for treating eosinophilic asthma via monoclonal 392	
antibodies to IL-5 itself or IL-5Ra31. IL-5 ligation in human eosinophils has been 393	
shown to activate the JAK/STAT pathway, specifically STAT540,41. With use of a 394	
specific STAT5 inhibitor we determined that increases in both ECAR and OCR upon 395	
IL-5 stimulation were dependent on STAT5 signalling. Because activated eosinophils 396	
increased their glucose utilization substantially, our attention turned to the PI3K/Akt 397	
axis as it is known to control glycolysis in other immune cell types such as T cells and 398	
macrophages42,43. PI3K and Akt inhibitors had a profound effect on the IL-5 mediated 399	
metabolic switch, especially glycolysis, showing that the IL-5 induced metabolic 400	
switch in human eosinophils is mediated by the STAT5/PI3K/Akt signalling axis. The 401	
IL-5 induced OCR was abrogated with PI3K inhibition but not Akt. This suggests that 402	
there are alternative downstream PI3K pathways contributing to increased oxygen 403	
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consumption, such as the PI3K/Rac pathway44. Respiratory burst in eosinophils has 404	
been closely linked previously with the Rac pathway, thus offering a plausible 405	
explanation for our observations15. Elucidating roles of multiple Akt-independent 406	
downstream PI3K targets and their contributions to eosinophil metabolism warrants 407	
further investigation.  408	
 409	
Finally, we considered the link between ROS production and metabolic pathway 410	
activity in eosinophils again focussing on the effects of IL-5. Treatment of eosinophils 411	
with IL-5 has been shown to induce ROS production23 and here we show that IL-5 412	
increases oxygen consumption. As NOX-dependent respiratory burst is a fundamental 413	
effector function of eosinophils14 we sought to investigate the role of ROS in eosinophil 414	
metabolism. Inhibiting NOX-dependent ROS production reduced the abundance of 415	
TCA cycle intermediates while increasing the accumulation of glucose-derived lactate 416	
suggesting that ROS may be a driver of eosinophil mitochondria metabolism in 417	
particular. This highlights that different bioactive molecules in the immediate 418	
microenvironment of eosinophils shape their metabolic plasticity.  419	
 420	
Our study outlines the metabolic requirements of mitochondria in cytokine-activated 421	
eosinophils. We also show that ROS may enable metabolic plasticity. Taken together, 422	
this provides further insight into the mechanistic control of eosinophil function. It is 423	
likely that terminally differentiated cells such as eosinophils do not require extensive 424	
energy production and biosynthesis to support homeostasis or activation. Instead 425	
multiple cytokines and important mediators such as eosinophil-derived neurotoxins and 426	
peroxidases are contained within pre-formed granules. However, cytokine-mediated 427	
activation clearly up-regulates cytoplasmic and mitochondrial metabolic pathways. 428	
This raises further questions about the links between eosinophil function and 429	
metabolism including the bioenergetic demands of piecemeal degranulation and the 430	
effects of mitochondrial DNA release on the metabolic status of eosinophils. 431	
Eosinophils are a characteristic feature of type 2 immune responses linked to 432	
immunopathology in asthma and other inflammatory disorders but also to tissue 433	
defence and repair processes in helminthic parasite infection45 and in other settings 434	
including metabolic homeostasis in adipose tissue6. Greater understanding of the 435	
regulation of eosinophil recruitment, retention and survival would provide mechanistic 436	
insight and offer new metabolically targeted therapeutic approaches for respiratory and 437	
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other eosinophilic diseases. Cell-specific delivery systems of pharmacological agents 438	
via for example Siglec-8 could be one route46 or more general approaches to limiting 439	
lacate in the tissue microenvironment during pathology might have broad effects on 440	
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Figure 1. IL-3, IL-5 or GM-CSF stimulated eosinophils increase glycolytic 650	
metabolism and production of lactate. (A) Expression levels of glucose transporters 651	
(GLUT) 1-4. (B) Representative flow cytometry plot of glucose uptake by eosinophils 652	
activated for 1 h with IL-3, IL-5 or GM-CSF (10 ng/mL) using probe 2-(N-(7-nitrobenz-653	
2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG; 100 μM). (C) Glycolytic 654	
stress profile of eosinophils by measuring extracellular acidification rate (ECAR; 655	
mpH/min) before and following addition of IL-3, IL-5, GM-CSF (10 ng/mL), glucose 656	
(5.5 mM), oligomycin (1 μM) and 2-DG (100 mM) at the time points indicated. (D) 657	
Post-glucose ECAR calculated via the averaged ECAR values from measurement 658	
points 7-9 minus the averaged ECAR values from measurement points 1-3. (E) 659	
Schematic of uniformly labelled 13C6-glucose incorporation into pyruvate and lactate. 660	
Eosinophils were activated with IL-3, IL-5, or GM-CSF (10 ng/mL) for 4 h. (F) 661	
Relative abundance of 12C and 13C pyruvate. (G) Mass isotopologue distribution (MID) 662	
of the pyruvate pool. (H) Relative abundance of 12C and 13C lactate including (I) MID 663	
of the lactate pool. (J) Relative abundance of 12C and 13C extracellular lactate. (K) 664	
Extracellular lactate production of eosinophils treated with IL-3, IL-5 or GM-CSF (10 665	
ng/mL) for 4 h. Data are represented as mean ± SEM of 7 (A), 4 (B), 3-5 (C-D, F-I), 2-666	
3 (J) and 2-4 (K) independent experiments with each data point representing an 667	
individual donor. Statistical analysis was performed using a one-way ANOVA with 668	
multiple comparisons to the control group (D, K) or a two-way ANOVA (F-J); * p ≤ 669	
0.05, ** p ≤ 0.01, *** p ≤ 0.001. 670	
 671	
Figure 2. Cytokine treatment induces mitochondrial-independent ROS 672	
production (A) Mitochondrial morphology of human eosinophils by TEM. (B) 673	
Oxidative stress assay measured via oxygen consumption rate (OCR; pmoles/min) 674	
before and following addition of IL-3, IL-5, GM-CSF (10 ng/mL), glucose (5.5 mM), 675	
oligomycin (1 μM) and 2-DG (100 mM) at the time points indicated. (C) Percentage 676	
OCR increase in comparison to baseline. (D) Glycolytic stress and (E) oxidative stress 677	
IL-3 dose response. Eosinophils were given IL-3 (10, 50 and 100 ng/mL), glucose (5.5 678	
mM), oligomycin (1 μM) and 2-DG (100 mM) at the time points indicated. (F) 679	
Representative flow cytometry plot and (G) MitoSOX+ve population of eosinophils 680	
activated with IL-3, IL-5 or GM-CSF (10 ng/mL) and incubated with MitoSOX for 15 681	
min. (H) Representative flow cytometry plots of total intracellular ROS production 682	
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measured by CellROX from one donor and (I) CellROX+ive population of eosinophils 683	
stimulated with IL-3, IL-5 or GM-CSF (10 ng/mL) ± DPI (10 μM). Dotted line indicates 684	
unstimulated controls in the presence of CellROX. Data expressed as mean ± SEM of 685	
2 (A), 3-5 (B-C), 2 (D-E), 4-5 (G) and 6-8 (I) independent experiments with each data 686	
point representing an individual donor. Statistical analysis was performed using a one-687	
way ANOVA with multiple comparisons to the control group (C) or an unpaired t test 688	
(I); * p ≤ 0.05, *** p ≤ 0.001. 689	
 690	
Figure 3. IL-3, IL-5 or GM-CSF treatment induces the production of TCA cycle 691	
intermediates. (A) Schematic of uniformly labelled 13C6-glucose incorporation into 692	
TCA cycle intermediates. Eosinophils were activated with IL-3, IL-5 or GM-CSF (10 693	
ng/mL) for 4 h. Relative abundance of 12C and 13C (B) citrate, (C) succinate, (D) malate 694	
and (E) fumarate. (F) Mass isotopologue distribution (MID) of m+2 citrate, succinate 695	
and malate. (G) Relative abundance of 12C and 13C glutamate including the (H) MID 696	
distribution. All data are from 3-6 independent experiments with each data point 697	
representing an individual donor. Data expressed as mean ± SEM. Statistical analysis 698	
was performed using a two-way ANOVA; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 699	
 700	
Figure 4. The STAT5/PI3K/Akt axis is responsible for the metabolic switch in IL-701	
5 treated eosinophils. (A) Representative immunoblot of eosinophils treated for 15 702	
min with IL-3, IL-5 or GM-CSF (10 ng/mL) for pSTAT5694 and β-actin. Corresponding 703	
densitometry analysis of pSTAT5 normalised to β-actin. (B) ECAR and (C) OCR 704	
before and following addition of a STAT5 inhibitor (STAT5i; Nʹ-((4-oxo-4H-chromen-705	
3-yl)methylene)nicotinohydrazide; 100 μM), IL-5 (10 ng/mL) and 2-DG (100 mM), 706	
including ‘pre-cytokine’ activation and ‘post-cytokine’ activation pooled OCR and 707	
ECAR data. (D) ECAR and (E) OCR before and following addition of a PI3K inhibitor 708	
(LY294002; 10 μM) or Akt1/2 inhibitor (1,3-Dihydro-1-(1-((4-(6-phenyl-1H-709	
imidazo[4,5-g]quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one 710	
trifluoroacetate salt hydrate; 10 μM), IL-5 (10 ng/mL) and 2-DG (100 mM). Data 711	
expressed as mean ± SEM of 5 (A), 2-3 (B-C) and 4 (D-E) independent experiments 712	
with each data point representing an individual donor. Statistical analysis was 713	
performed using a Friedman test with Dunn’s multiple comparisons (A) or a two-way 714	
21	
	
ANOVA with Sidak’s multiple comparison test (B-E); * p ≤ 0.05, ** ≤ p 0.01, *** p ≤ 715	
0.001. 716	
 717	
Figure 5. DPI inhibits oxidative metabolism in IL-5 stimulated eosinophils. (A) 718	
ECAR (mpH/min) and (B) OCR (pmoles/min) of eosinophils treated with IL-5 (10 719	
ng/mL) ± DPI (100 nM), glucose (5.5 mM), oligomycin (1 μM) and 2-DG (100 mM). 720	
Eosinophils were activated with IL-5 (10 ng/mL) ± DPI (100 nM) for 4 h in the presence 721	
of 13C-glucose. (C) Relative abundance of 12C and 13C and (D) mass isotopologue 722	
distribution (MID) of glycolytic intermediates pyruvate and lactate. (E) Relative 723	
abundance of 12C and 13C and (F) MID of TCA cycle intermediates citrate, succinate, 724	
fumarate and malate. (G) Relative abundance of 12C and 13C and (H) MID of amino 725	
acids glutamate and aspartate. Data expressed as mean ± SEM of 4 (A-B) and 3 (C-H) 726	
independent experiments with each data point representing an individual donor. 727	
Statistical analysis was performed using an unpaired t test (B) or a two way ANOVA 728	
(C-H); * p ≤ 0.05, ** ≤ p 0.01, *** p ≤ 0.001. 729	
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